Table 2 Characteristics of patients at baseline and after 6Â months of treatment
From: Effects of a new nutraceutical combination on cognitive function in hypertensive patients
| Â | Baseline | 6-months | Treatment effecta |
|---|---|---|---|
SBP (mmHg) | Â | Â | Â |
 Control group | 133.3 ± 16.9 | 133.1 ± 15.7 | 0.132 |
 Active treatment group | 135.6 ± 13.5 | 130.6 ± 11.4 | |
DBP (mmHg) | Â | Â | Â |
 Control group | 84.1 ± 12.3 | 83.1 ± 8.8 | 0.402 |
 Active treatment group | 85.8 ± 9.1 | 81.5 ± 8.5 | |
Heart rate (bpm) | Â | Â | Â |
 Control group | 68.8 ± 6.8 | 68.2 ± 5.3 | 0.209 |
 Active treatment group | 66.4 ± 7.9 | 68.3 ± 8.3 | |
Total cholesterol (mg/dl) | Â | Â | Â |
 Control group | 198.2 ± 23.7 | 210.8 ± 21.7 | 0.132 |
 Active treatment group | 201.9 ± 27.5 | 204.4 ± 23.6 | |
HDL cholesterol (mg/dl) | Â | Â | Â |
 Control group | 47.6 ± 7.9 | 51.3 ± 11.9 | 0.740 |
 Active treatment group | 51.3 ± 7.2 | 54.3 ± 7.7 | |
LDL cholesterol (mg/dl) | Â | Â | Â |
 Control group | 129.2 ± 26.1 | 138.9 ± 22.4 | 0.179 |
 Active treatment group | 126.7 ± 30.4 | 126.9 ± 25.0 | |
Triglycerides (mg/dl) | Â | Â | Â |
 Control group | 107.1 ± 34.8 | 103.1 ± 35.0 | 0.946 |
 Active treatment group | 119.5 ± 27.9 | 115.9 ± 24.3 | |
Glycaemia (mg/dl) | Â | Â | Â |
 Control group | 95.7 ± 11.2 | 96.6 ± 13.3 | 0.746 |
 Active treatment group | 93.1 ± 7.5 | 93.0 ± 8.0 | |
Augmentation Index (%) | Â | Â | Â |
 Control group | 14.19 ± 10.00 | 14.69 ± 11.79 | 0.028 |
 Active treatment group | 18.59 ± 18.21 | 12.24 ± 12.30 |